Protagonist Therapeutics, Inc (PTGX): Nasdaq/NYSE listing notice — Protagonist Therapeutics receives Nasdaq non-compliance notice for audit committee vacancy

Protagonist Therapeutics, Inc

On June 27, 2023, Nasdaq confirmed Protagonist is not compliant with Listing Rule 5605 requiring an audit committee of at least three independent directors.
The vacancy arose after Sarah Noonberg, M.D., Ph.D. did not stand for re-election at the May 25, 2023 annual meeting.
Company has a cure period until the earlier of its next annual meeting or May 27, 2024 to fill the audit committee seat.
Board is in the process of identifying and selecting a new independent director to meet Nasdaq requirements.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 1.0

Protagonist Therapeutics, Inc received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4), 5605(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605, 5605(c)(4), 5605(a)(2)

Exact text from the filing

June 27, 2023, the Company received a letter from Nasdaq confirming that t he Company is no longer in compliance with Nasdaq’s audit committee composition requirements as set forth in Nasdaq Listing Rule 5605, which requires that the audit committee of a listed company be comprised of at least three “independent directors” (as defined in Nasdaq Listing Rule 5605(a)(2)). Pursuant to Nasdaq Listing Rule 5605(c)(4), the Company intends to rely on the cure period to reestablish compliance with Nasdaq Listing Rule 5605. The cure period is generally defined as until the earlier of the Company’s next

View on SEC.gov

Browse all listing & compliance notices →

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-077599

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.